CannaPharmaRX Has Cease Trade Order Revoked, Plans Restructuring

Cannapharmarx ( (CPMD) ) has provided an update.

On December 12, 2025, CannaPharmaRX announced that the British Columbia Securities Commission revoked the failure-to-file cease trade order imposed on May 11, 2023, after the company completed its previously delinquent 2022 annual filings with Canadian and U.S. regulators by October 19, 2023. Despite the lifting of the trading restriction, the company reported substantial going-concern risks, including a working capital deficit of $27.0 million and significant related-party debt of $10.8 million plus accrued interest as of September 30, 2025, and outlined a strategic plan centered on debt restructuring, securing working capital, ramping up production capacity at its Alberta facility, and expanding into European markets to strengthen its financial position and long-term viability.

Spark’s Take on CPMD Stock

According to Spark, TipRanks’ AI Analyst, CPMD is a Underperform.

Cannapharmarx presents a high-risk investment due to severe financial instability, reflected in negative equity and cash flow issues. The absence of technical analysis indicators further adds uncertainty. Without any positive valuation metrics or corporate events to offset the risks, the stock score is significantly low.

To see Spark’s full report on CPMD stock, click here.

More about Cannapharmarx

CannaPharmaRX, Inc. operates in the cannabis industry, focusing on cannabis production at its Cremona, Alberta facility, where six of ten growing rooms are currently operational. The company is pursuing expansion in European markets, particularly Germany and Israel, and aims to obtain EU-GMP certification to enable direct shipment of products to EU countries and reduce logistics costs and timelines.

Technical Sentiment Signal: Sell

Current Market Cap: $2.65M

For a thorough assessment of CPMD stock, go to TipRanks’ Stock Analysis page.